ShuYu Civilian Pharmacy Corp. Ltd. (301017) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of ShuYu Civilian Pharmacy Corp. Ltd. stock ¥5.91, price ¥14.34, that is 58.8% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range ¥8.94 – ¥34.23 · fair‑value band ¥4.44 – ¥7.39 · the ¥14.34 price screens above the ¥5.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow ShuYu Civilian Pharmacy Corp. in your weekly email
Every Wednesday you see whether ShuYu Civilian Pharmacy Corp. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ShuYu Civilian Pharmacy Corp., Ltd. engages in the pharmaceutical retail chain business in China. The company is also involved in the pharmaceutical wholesale business. ShuYu Civilian Pharmacy Corp., Ltd. was founded in 1999 and is based in Jinan, China.
Stock analysis
ShuYu Civilian Pharmacy Corp. Ltd. (301017) currently trades at ¥14.34, while our model-based Fair Value estimate is ¥5.91, 59% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥25.04 per share, and 11 of the 24 models we run sit above the ¥14.34 price.
Bear case: the Dividend Discount group reads lowest at ¥3.21, and 13 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥4.44 (bear) to ¥7.39 (bull), the price of ¥14.34 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
ShuYu Civilian Pharmacy Corp. Ltd. reported revenue of 10.3B CNY in FY2025 versus 5.3B CNY in FY2021, a compound +18.0%/yr. Reported net income was 114M CNY in FY2025, compounding −0.2%/yr from FY2021.
Key figures
Market cap 5.8B CNY (≈ $872M) Small · P/E ratio 239.0 · P/S ratio 0.54 · EPS (TTM) ¥0.0600 · Dividend yield 0.3% · Net margin 0.3% · Return on equity 2.2% · Return on assets (EBIT) 3.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 19% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 40% fair-value upside, at −59%, 301017 screens richer than that median.
Fair Value models
Bear¥4.44Fair Value ¥5.91Bull¥7.39
Price ¥14.34 · Downside -58.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.0128 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.0%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+4.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.8%
Dividend (yield on the price)0.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 2%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −2.2% a year for the price.
Compare ShuYu Civilian Pharmacy Corp. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 2/13 measures
Overall it trails its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−58.8% · Bottom 25%
Profitability
Return on equity (12 months)2.2% · Bottom 25%
Return on assets1.2% · Bottom 25%
Net margin (12 months)0.3% · Bottom 25%
Operating margin (12 months)1.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)3.6% · Below median
Dividend yield (12 months)0.3% · Bottom 25%
Balance sheet
Debt / equity0.56× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (12 months)239.0× · Priciest 25%
P/B2.73× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)0.54× · Pricier than median
Price / free cash flow (fiscal year)9.2× · Cheaper than median
EV/EBITDA19.2× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 66
FUTURE (revenue growth)18· sector 21
PAST (return on equity)9· sector 32
HEALTH (low debt)72· sector 96
DIVIDEND (yield)6· sector 58
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ShuYu Civilian Pharmacy Corp. Ltd. (301017) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥5.91 versus a price of ¥14.34, about 59% lower (overvalued).
What is the fair value of 301017?
Our model-based fair value for ShuYu Civilian Pharmacy Corp. Ltd. is ¥5.91 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥14.34.
What is the quality score of 301017?
ShuYu Civilian Pharmacy Corp. Ltd. has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
Our model-based price target is the fair value of ¥5.91 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario ¥4.44, optimistic scenario ¥7.39. It is a calculation from audited fundamentals, not an analyst target.
What is the ShuYu Civilian Pharmacy Corp. Ltd. stock forecast for 2026?
Our models put fair value at ¥5.91, about 59% lower versus a price of ¥14.34 (overvalued). Cautious scenario ¥4.44, optimistic scenario ¥7.39. The calculation is refreshed regularly with new filings.
What is the revenue of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
ShuYu Civilian Pharmacy Corp. Ltd. reported trailing-twelve-month revenue of about 10.9B CNY (latest available figure, as of Nov 7, 2026).
Does ShuYu Civilian Pharmacy Corp. Ltd. pay a dividend?
ShuYu Civilian Pharmacy Corp. Ltd. currently shows a dividend yield of 0.31% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of ShuYu Civilian Pharmacy Corp. Ltd. (301017) and when is the ex-dividend date?
ShuYu Civilian Pharmacy Corp. Ltd. pays a dividend of ¥0.045 per share a year, a dividend yield of 0.3%. The last ex-dividend date was Jun 3, 2026. The payout ratio is 75.0% of earnings. Free cash flow covers the dividend 34.54 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
For today's price to be fair in a discounted-cash-flow model, ShuYu Civilian Pharmacy Corp. Ltd. would have to grow free cash flow by -0.6 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.4 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 301017 use?
Our models discount ShuYu Civilian Pharmacy Corp. Ltd. at 10.4 %: a base by market capitalisation (small), damped by beta 0.44, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ShuYu Civilian Pharmacy Corp. Ltd. that is -0.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has ShuYu Civilian Pharmacy Corp. Ltd. (301017) delivered so far?
Over the past 5 years revenue at ShuYu Civilian Pharmacy Corp. Ltd. grew +17.4 % a year. The price currently implies free-cash-flow growth of -0.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ShuYu Civilian Pharmacy Corp. Ltd. (301017) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into ShuYu Civilian Pharmacy Corp. Ltd. (-0.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
The free-cash-flow yield on the price is 10.85 %: that much free cash flow ShuYu Civilian Pharmacy Corp. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ShuYu Civilian Pharmacy Corp. Ltd. it is ¥5.91 per share (as of Nov 7, 2026), against a price of ¥14.34. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is ShuYu Civilian Pharmacy Corp. Ltd. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 301017 trades above its calculated fair value: price ¥14.34, fair value ¥5.91, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301017?
No. The price is what the market pays today (¥14.34); the fair value is what the company's own numbers justify (¥5.91). For ShuYu Civilian Pharmacy Corp. Ltd. the two are ¥8.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is ShuYu Civilian Pharmacy Corp. Ltd. worth?
The market values ShuYu Civilian Pharmacy Corp. Ltd. at about 5.8B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥14.34; our models calculate a fair value of ¥5.91 per share.
What do the bullish and bearish scenarios say about 301017?
Our models span a range for ShuYu Civilian Pharmacy Corp. Ltd.: cautious scenario ¥4.44, base ¥5.91, optimistic ¥7.39 per share (as of Nov 7, 2026, price ¥14.34). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301017?
ShuYu Civilian Pharmacy Corp. Ltd. trades at a price-to-earnings ratio of 239.0 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥5.91 is built from several models across several years. Other multiples: P/B 2.7, P/S 0.5, EV/EBITDA 19.2.
How solid is the balance sheet of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
Balance-sheet figures for ShuYu Civilian Pharmacy Corp. Ltd. (as of Nov 7, 2026): return on equity 2.2%, debt of 0.56 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 301017 from its 52-week high?
ShuYu Civilian Pharmacy Corp. Ltd. trades at ¥14.34, about 33% below its 52-week high of ¥21.38 and 19% above the low of ¥12.04 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥5.91 is for.
Which stocks are comparable to ShuYu Civilian Pharmacy Corp. Ltd.?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ShuYu Civilian Pharmacy Corp. Ltd. stock attractive at the current price?
The data as of Nov 7, 2026: price ¥14.34, calculated fair value ¥5.91 (−59%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301017 calculated?
We run ShuYu Civilian Pharmacy Corp. Ltd. through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥5.91 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. ShuYu Civilian Pharmacy Corp. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
The closing price on Nov 6, 2026 was ¥14.34. Our model-based fair value is ¥5.91, about 59% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ShuYu Civilian Pharmacy Corp. Ltd. right now?
The price sits above even our optimistic bull case (¥7.39). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of ShuYu Civilian Pharmacy Corp. Ltd.
How large is the market capitalisation of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
The market capitalisation of ShuYu Civilian Pharmacy Corp. Ltd. is 5.8B CNY (≈ $872M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
The price-to-sales ratio of ShuYu Civilian Pharmacy Corp. Ltd. is 0.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
Earnings per share at ShuYu Civilian Pharmacy Corp. Ltd. are ¥0.0600 (price ÷ EPS = P/E 239.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
The dividend yield of ShuYu Civilian Pharmacy Corp. Ltd. is 0.3% (payout 75.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
The net margin of ShuYu Civilian Pharmacy Corp. Ltd. is 0.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
The return on equity (ROE) of ShuYu Civilian Pharmacy Corp. Ltd. is 2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
On an EBIT basis the return on assets of ShuYu Civilian Pharmacy Corp. Ltd. is 3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
The operating margin of ShuYu Civilian Pharmacy Corp. Ltd. is 1.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
Revenue at ShuYu Civilian Pharmacy Corp. Ltd. is growing +3.6% versus a year earlier (3y avg +9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
Earnings per share at ShuYu Civilian Pharmacy Corp. Ltd. are growing +6.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does ShuYu Civilian Pharmacy Corp. Ltd. (301017) carry?
The net debt of ShuYu Civilian Pharmacy Corp. Ltd. is 822M CNY (fiscal year 2025, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ShuYu Civilian Pharmacy Corp. Ltd. in the live analysis
One click puts ShuYu Civilian Pharmacy Corp. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026